AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
August 08, 2023 08:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the completion of enrollment in the company’s Phase 2 study evaluating Ampligen® as a...
BrainHQ selected for NIH-funded Study for Long Covid Cognitive Issues
August 02, 2023 08:00 ET
|
Posit Science
SAN FRANCISCO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- As announced by the US National Institutes of Health (NIH), BrainHQ is being incorporated into phase 2 clinical trials addressing persistent...
Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
July 26, 2023 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Vielight Starts Clinical Trial to Study Photobiomodulation Device Treatment for Post-Covid Cognitive Impairment
July 26, 2023 10:33 ET
|
Vielight Inc.
Toronto, Canada, July 26, 2023 (GLOBE NEWSWIRE) -- Vielight Inc. announced it has commenced a new clinical trial in the United States to study how brain stimulation photobiomodulation (PBM)...
$2.34Bn Growth for Mice Model Market Size to Hit 5.4% CAGR with CRISPR Segment Driving Growth During 2022-2028
July 25, 2023 09:19 ET
|
The Insight Partners
Pune, India, July 25, 2023 (GLOBE NEWSWIRE) -- According to Recently Published Report by The Insight Partners, “Mice Model Market Size Report and Forecast to 2028 - COVID-19 Impact and Global...
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
July 24, 2023 08:30 ET
|
Dyadic International, Inc.
Dosing of patients completed at the end of FebruaryData Safety Monitoring Board conducted analysis of Day 29 data No major vaccine-related safety concerns for either of the two dose levelsNo Serious...
DHR EQUITY ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Danaher Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – DHR
July 19, 2023 15:36 ET
|
The Rosen Law Firm PA
NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Danaher...
LEX Diagnostics Appoints Chief Technology Officer
July 18, 2023 03:00 ET
|
LEX Diagnostics
CAMBRIDGE, United Kingdom, July 18, 2023 (GLOBE NEWSWIRE) -- LEX Diagnostics (LEX) today announces the appointment of Dr Heather Danks as its Chief Technology Officer (CTO). The company is...
Kinarus Therapeutics Announces Personnel Change
July 12, 2023 01:00 ET
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
July 10, 2023 08:05 ET
|
AIM ImmunoTech Inc.
Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 ...